Valuation: Shenzhen Chipscreen Biosciences Co., Ltd.

Capitalization 1.13TCr 167.06Cr 144.68Cr 132.75Cr 124.9Cr 232.62Cr 16TCr 236.26Cr 1.58TCr 614.11Cr 7.7TCr 627.3Cr 613.65Cr 27TCr P/E ratio 2024
-66.2x
P/E ratio 2025 234x
Enterprise value 1.22TCr 180.4Cr 156.22Cr 143.35Cr 134.87Cr 251.19Cr 17TCr 255.12Cr 1.7TCr 663.12Cr 8.31TCr 677.36Cr 662.62Cr 29TCr EV / Sales 2024
12.2x
EV / Sales 2025 14.1x
Free-Float
69.1%
Yield 2024 *
-
Yield 2025 0.2%
22/05 Zhejiang Ruijiu Equity Investment Co., Ltd. acquired an additional 5% stake in Shenzhen Chipscreen Biosciences Co., Ltd. from Shenzhen Haiyuemen Biotechnology Development Co., Ltd., and Shenzhen Haide Xincheng Enterprise Management Partnership Enterprise (Limited Partnership) for approximately CNY 570 million. CI
15/05 Shenzhen Chipscreen Biosciences Gets Macau Approval for Diabetes Drug MT
29/04 Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 10, 2026. CI
30/03 Shenzhen Chipscreen Biosciences Co., Ltd. announces Annual dividend, payable on May 14, 2026 CI
10/03 Shenzhen Chipscreen Biosciences Co., Ltd. announces an Equity Buyback for CNY 120 million worth of its shares. CI
09/03 Shenzhen Chipscreen Biosciences Co., Ltd. authorizes a Buyback Plan. CI
02/03 Shenzhen Chipscreen Biosciences Co., Ltd. announced that it has received CNY 949.999997 million in funding CI
26/02 Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
27/01 Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025 MT
09/01 Chipscreen Biosciences Gets Nod for Xioronni Capsules' Clinical Trials MT
08/01 Shenzhen Chipscreen Biosciences Gets Macao Marketing Approval for Cancer Drug MT
02/01 Chinese Drug Regulator Accepts Clinical Trial Application of Chipscreen Biosciences' Unit for CS08399 Tablets MT
1 day-0.82%
1 week-5.89%
Current month-5.89%
1 month-20.65%
3 months-16.09%
6 months-7.59%
Current year-12.56%
1 week 25.42
Extreme 25.42
27.87
1 month 25.42
Extreme 25.42
32.4
Current year 25.42
Extreme 25.42
36.47
1 year 20.8
Extreme 20.8
44.99
3 years 12.47
Extreme 12.47
44.99
5 years 12.47
Extreme 12.47
47.76
10 years 12.47
Extreme 12.47
125
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/05/2001
Chief Executive Officer 63 24/03/2018
Director of Finance/CFO 55 01/06/2001
Director TitleAgeSince
Chairman 63 24/03/2018
Director/Board Member 55 24/03/2018
Director/Board Member 48 24/03/2018
Date Insider Type Main position Quantity % Market Cap.
03/24/03Sell 12,500 0.0030%
02/24/02Sell

Director

7,30,000 0.1775%
09/23/09Buy 12,500 0.0030%
Change 5d. change 1-year change 3-years change Capi.($)
-0.82%-5.89%+11.57%+18.29% 167.06Cr
+0.44%+1.74%+52.96%+9.80% 30TCr
-1.90%+4.59%+18.79%-19.74% 6.87TCr
-0.10%+7.50%+31.85%+110.51% 848.44Cr
-0.46%-8.62%-5.96%-16.97% 747.68Cr
-2.65%-1.78%-2.54%+18.57% 443.49Cr
-3.25%-8.82%-25.34%+33.62% 371.67Cr
+1.66%-7.21%-21.79%-8.15% 303.59Cr
+0.11%-3.10%+34.99%+29.37% 259.73Cr
+0.71%-3.88%-1.20%-19.16% 194.91Cr
Average -0.63%-2.39%+9.33%+15.61% 4TCr
Weighted average by Cap. -0.06%+1.88%+43.09%+6.57%

Financials

2024 2025
Net sales 66Cr 9.71Cr 8.41Cr 7.72Cr 7.26Cr 14Cr 925.56Cr 14Cr 92Cr 36Cr 447.61Cr 36Cr 36Cr 1.56TCr 91Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.28TCr 19Cr 126.89Cr 49Cr 619.12Cr 50Cr 49Cr 2.15TCr
Net income -11Cr -1.69Cr -1.46Cr -1.34Cr -1.26Cr -2.36Cr -161.17Cr -2.39Cr -16Cr -6.22Cr -78Cr -6.35Cr -6.21Cr -271.05Cr 5.1Cr 75.23L 65.15L 59.78L 56.24L 1.05Cr 72Cr 1.06Cr 7.11Cr 2.77Cr 35Cr 2.82Cr 2.76Cr 120.56Cr
Net Debt 48Cr 7.08Cr 6.13Cr 5.63Cr 5.29Cr 9.86Cr 674.59Cr 10Cr 67Cr 26Cr 326.24Cr 27Cr 26Cr 1.13TCr 90Cr 13Cr 12Cr 11Cr 9.97Cr 19Cr 1.27TCr 19Cr 125.93Cr 49Cr 614.45Cr 50Cr 49Cr 2.14TCr
Logo Shenzhen Chipscreen Biosciences Co., Ltd.
Shenzhen Chipscreen Biosciences Co Ltd is a China-based company primarily engaged in the research, development, production and sales of original innovative pharmaceuticals. The products primarily include the epigenetic regulator Epidaza (chidamide), the insulin sensitizer Bilessglu (chiglitazar), the triple-pathway tumor inhibitor chiauranib, the small-molecule PD-L1 inhibitor CS23546, the brain-penetrating Aurora B selective inhibitor CS231295 and the highly selective small-molecule allosteric inhibitor CS32582 for tyrosine kinase 2 (TYK2). The Company is also engaged in the development of drugs such as CS1011, CS08399 and CS25141, as well as the licensing of research and development technologies. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States.
Employees
1,002
Date Price Change Volume
05/26/05 25.55 ¥ -0.82% 71,22,320
04/26/04 25.76 ¥ -3.12% 81,78,602
03/26/03 26.59 ¥ -0.08% 70,33,329
02/26/02 26.61 ¥ -2.13% 75,76,549
01/26/01 27.19 ¥ +0.15% 93,33,565

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688321 Stock